StockFame
  • Trending News
  • Markets
  • US Markets
  • Indian Stocks
  • Economics
  • Crypto News
Select Page

The $100 Million Liraglutide Pivot: Why Biocon Is Prioritising US Exports Over The Indian Price War

by NDTV Profits | March 17, 2026 4:31 pm | Latest Posts, Market, Trending News

While Liraglutide provides immediate momentum, the industry is eyeing 2031, the year Semaglutide patents expire in the US and Europe.

Recent Posts

  • Maruti Suzuki Receives Tax Notice Worth Over Rs 5,700 Crore; Details Here
  • Chaitra Navratri 2026: Day-Wise Colours List, Significance And All You Need To Know
  • ‘Banks Collected Rs 19,000 Crore In 3 Years’: Raghav Chadha Proposes Ending Minimum Balance Penalties
  • Zydus, Lupin sign pact to distribute Semaglutide weight- loss injections for diabetes care in India: Check details
  • US stock market today: Dow, S&P 500 futures slip as Brent crude oil prices rebound to $105

About Stockfame

Stockfame is a global media platform delivering bold insights on business, markets, technology, leadership, and entrepreneurship. We bring you research-backed news and sharp analysis to help you stay ahead of the curve.

Quick News Links

  • Crypto News
  • Indian Stocks
  • Latest Posts
  • Market
  • News
  • Trending News
  • US Markets

Contact Us

Reach out to us at:
Phone:  [+91] 9834938257
Email: contact@stockfame.com
For Advertisement, Press Releases, Partnerships or to get backlinks on this website, please e-mail us at contact@stockfame.com

Quick Reads

  • Global market news
  • Crypto Market News
  • Indian Market News
  • Economy News
  • Latest Business News
  • About
  • Terms and Conditions
  • Privacy Policy
  • Website User Agreement
  • Disclaimer
  • Facebook
  • X
  • Instagram
  • RSS
Copyright @StockFame | All Rights Reserved